A Study to Evaluate the Effectiveness and Safety of an Implant in the Treatment of Osteoarthritis of the Great Toe
1 other identifier
interventional
236
2 countries
12
Brief Summary
This study will evaluate whether Cartiva is an effective treatment for individuals with osteoarthritis of the great toe.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Aug 2009
Longer than P75 for phase_3
12 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2009
CompletedFirst Submitted
Initial submission to the registry
September 1, 2009
CompletedFirst Posted
Study publicly available on registry
September 2, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2016
CompletedNovember 15, 2016
November 1, 2016
6.9 years
September 1, 2009
November 10, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
VAS, FAAM, Safety
The individual components of the primary outcome measures will be Visual Analog Scale (VAS) Pain, Foot and Ankle Ability Measure (FAAM) Sports sub-scale score and absence of key safety issues.
up to 2 years
Study Arms (2)
Arthrodesis
ACTIVE COMPARATORFusion
Cartiva
EXPERIMENTALSynthetic Cartilage Implant
Interventions
Eligibility Criteria
You may qualify if:
- ≥ 18 years of age
- Osteoarthritis of the first metatarsophalangeal joint and is a candidate for arthrodesis
- Presence of good bone stock
- Capable of completing self-administered questionnaires
You may not qualify if:
- \< 18 years of age
- Osteoarthritis of the first metatarsophalangeal joint, though is not a candidate for arthrodesis
- Active bacterial infection of the foot
- Additional ipsilateral limb (hip, knee, ankle, or foot) pathology that requires active treatment (surgery or brace)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cartiva, Inc.lead
Study Sites (12)
University of Calgary
Calgary, Alberta, T2N 4N1, Canada
University of Alberta
Edmonton, Alberta, Canada
St. Paul's Hospital
Vancouver, British Columbia, V6Z 1Y6, Canada
Horizon Health Network
Fredericton, New Brunswick, E3B 5N5, Canada
Queen Elizabeth Science Centre
Halifax, Nova Scotia, B3H 3A7, Canada
St. Michael's Hospital
Toronto, Ontario, M5C 1R6, Canada
Frimley Park Hospital - Surrey Foot and Ankle Clinic
Frimley, Camberley, GU16 7UJ, United Kingdom
St. George's Hospital
Tooting, London, SW17 0QT, United Kingdom
Royal National Orthopaedic Hospital - Stanmore Foot & Ankle Clinic
Stanmore, Middlesex, HA7 4LP, United Kingdom
Northern General Hospital NHS Trusts - Sheffield Orthopaedics
Sheffield, South Yorkshire, S5 7AU, United Kingdom
Royal Surrey County Hospital
Guildford, Surrey, GU2 5XX, United Kingdom
Torbay Hospital
South Devon, Torquay, TQ2 7AA, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Judith Baumhauer
University of Rochester
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 1, 2009
First Posted
September 2, 2009
Study Start
August 1, 2009
Primary Completion
July 1, 2016
Study Completion
July 1, 2016
Last Updated
November 15, 2016
Record last verified: 2016-11
Data Sharing
- IPD Sharing
- Will not share